Review article: current and emerging therapies for functional dyspepsia
Article first published online: 12 JUL 2006
Alimentary Pharmacology & Therapeutics
Volume 24, Issue 3, pages 475–492, August 2006
How to Cite
SAAD, R. J. and CHEY, W. D. (2006), Review article: current and emerging therapies for functional dyspepsia. Alimentary Pharmacology & Therapeutics, 24: 475–492. doi: 10.1111/j.1365-2036.2006.03005.x
- Issue published online: 12 JUL 2006
- Article first published online: 12 JUL 2006
- Publication data Submitted 13 February 2006 First decision 26 February 2006 Resubmitted 15 May 2006 Accepted 15 May 2006
Functional dyspepsia represents a heterogeneous group of gastrointestinal disorders marked by the presence of upper abdominal pain or discomfort. Although its precise definition has evolved over the last several decades, this disorder remains shrouded in controversy. The symptoms of functional dyspepsia may overlap with those of other functional bowel disorders including irritable bowel syndrome and non-erosive reflux disease.
There may be coexistent psychological distress or disease complicating its presentation and response to therapy. Given the prevalence and chronicity of functional dyspepsia, it remains a great burden to society. Suspected physiological mechanisms underlying functional dyspepsia include altered motility, altered visceral sensation, inflammation, nervous system dysregulation and psychological distress. Yet the exact pathophysiological mechanisms that cause symptoms in an individual patient remain difficult to delineate. Numerous treatment modalities have been employed including dietary modifications, pharmacological agents directed at various targets within the gastrointestinal tract and central nervous system, psychological therapies and more recently, complementary and alternative treatments.
Unfortunately, to date, all of these therapies have yielded only marginal results. A variety of emerging therapies are being developed for functional dyspepsia. Most of these therapies are intended to normalize pain perception and gastrointestinal motor and reflex function in this group of patients.